Erschienen in:
11.11.2017 | Original Paper
Monitoring and Treating Metabolic Abnormalities in Patients with Early Psychosis Initiated on Antipsychotic Medications
verfasst von:
Kevin M. Bozymski, Jessica A. Whitten, Mary E. Blair, Ashley M. Overley, Carol A. Ott
Erschienen in:
Community Mental Health Journal
|
Ausgabe 6/2018
Einloggen, um Zugang zu erhalten
Abstract
Antipsychotic medications carry an established lifetime risk of metabolic syndrome. This retrospective chart review evaluated feasibility of a metabolic monitoring clinical decision support tool (CDST) for weight, lipid, blood glucose, and blood pressure management of 163 clients in an early psychosis outpatient clinic over 2 years. Each parameter had at least 98 (60.1%) clients with a recorded value, the most being documented for weight with 112 (68.7%) clients. CDST adherence ranged from at least 54.3–100% for non-pharmacologic interventions (e.g. clinic counseling, referral to health program or primary care) and at least 33.3–100% for pharmacologic interventions (e.g. metformin). Though no baseline cardiometabolic abnormalities were identified, dyslipidemia and obesity were later found in 37 (22.7%) and 35 (21.5%) clients, respectively. Only 14 (8.6%) clients were prescribed medications for cardiometabolic abnormalities by psychiatrists in the clinic. Increasing focus on physical health is needed to better this population’s long-term prognosis.